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1. Introduction 
Nanoscience has been variously defined at different fora, books, journals and the web, yet 
one thing is common; it involves the study of the control of matter on an atomic and 
molecular scale. This molecular level investigation is at a range usually below 100 nm. In 
simple terms, a nanometer is one billionth of a meter and the properties of materials at this 
atomic or subatomic level differ significantly from properties of the same materials at larger 
sizes. Although, the initial properties of nanomaterials studied were for its physical, 
mechanical, electrical, magnetic, chemical and biological applications, recently, attention has 
been geared towards its pharmaceutical application, especially in the area of drug delivery. 
This is because of the challenges with use of large size materials in drug delivery, some of 
which include poor bioavailability, in vivo stability, solubility, intestinal absorption, 
sustained and targeted delivery to site of action, therapeutic effectiveness, generalized side 
effects, and plasma fluctuations of drugs. Of recent, several researches in nanodrug delivery 
have been designed to overcome these challenges through the development and fabrication 
of nanostructures. It has been reported that, nanostructures have the ability to protect drugs 
from the degradation in the gastrointestinal tract, the technology can allow target delivery of 
drugs to various areas of the body. The technology enables the delivery of drugs that are 
poorly water soluble and can provide means of bypassing the liver, thereby preventing the 
first pass metabolism Nanotechnology increases oral bioavailability of drugs due to their 
specialized uptake mechanisms such as absorptive endocytosis and are able to remain in the 
blood circulation for a long time, releasing the incorporated drug in a controlled fashion, 
leading to less plasma fluctuations and minimized side-effects. Nanoscale size 
nanostructures are able to penetrate tissues and are easily taken up by cells, allowing for 
efficient delivery of drugs to target sites of action. Uptake of nanostructures has been 
reported to be 15–250 times greater than that of microparticles in the 1–10 um range. 
Nanotechnology improves performance and acceptability of dosage forms by increasing 
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their effectiveness, safety, patient adherence, as well as ultimately reducing health care 
costs. It may also enhance the performance of drugs that are unable to pass clinical trial 
phases. Nanotechnology definitely promises to serve as drug delivery carrier of choice for 
the more challenging conventional drugs used for the treatment and management of chronic 
diseases such as cancer, asthma, hypertension, HIV and diabetes.  
2. Nanotechnology-based drug delivery systems  
2.1. Smart drug delivery systems 
Ideally, nanoparticulate drug delivery system should selectively accumulate in the required 
organ or tissue and at the same time, penetrate target cells to deliver the bioactive agent. It 
has been suggested (1, 2) that, organ or tissue accumulation could be achieved by the 
passive or antibody-mediated active targeting (3, 4), while the intracellular delivery could be 
mediated by certain ligands (5, 6) or by cell-penetrating peptides (7, 8). Thus, a drug 
delivery system (DDS) should be multifunctional and possess the ability to switch on and 
switch off certain functions when necessary. Another important requirement is that different 
properties of the multifunctional DDS are coordinated in an optimal fashion. Thus, for 
example, if the system is to be constructed that can provide the combination of the longevity 
allowing for the target accumulation and specific cell surface binding allowing, two 
requirements must be met; the half-life of the carrier in the circulation should be long 
enough and second, the internalization of the DDS by the target cells should proceed fast 
enough not to allow for the carrier degradation and drug loss in the interstitial space.  
Intracellular transport of bioactive molecules is one of the key problems in drug delivery. 
Nanoparticulate DDS, such as liposomes and micelles, are frequently used to increase the 
efficacy of drug and DNA delivery and targeting (9, 10). So far, very few successful attempts 
have been made to deliver various drug carriers directly into the cell cytoplasm, bypassing 
the endocytic pathway, to protect drugs and DNA from the lysosomal degradation, thus 
enhancing drug efficiency and DNA incorporation into the cell genome (11-14). Within the 
multifunctional DDS, it has been postulated that, the development of a DDS built in such a 
way that during the first phase of delivery, a nonspecific cell-penetrating function is 
shielded by the organ/tissue-specific delivery will be possible. Upon accumulating in the 
target, protecting polymer or antibody attached to the surface of the DDS via the stimuli-
sensitive bond should detach under the action of local pathological conditions such as 
abnormal pH or temperature and expose the previously hidden second function allowing 
for the subsequent delivery of the carrier and its cargo inside cells. While such DDS should 
be stable in the blood for a long time to allow for an efficient target accumulation, it has to 
lose the protective coat inside the target almost instantly to allow for fast internalization 
thereby minimizing the washing away of the released drug or DNA. Intracellular 
trafficking, distribution, and fate of the carrier and its cargo can be additionally controlled 
by its charge and composition, which can drive it to the nuclear compartment or toward 
other cell organelles. 
It has been reported within the past few years, that certain proteins and peptides (such as 
TAT peptide) can enter cell cytoplasm directly and even target cell nuclei (15, 16). Certain 
 
Nanotechnology in Drug Delivery 71 
proteins and peptides have also been used for the intracellular delivery of small drug 
molecules, large molecules (enzymes, DNA), and nanoparticulates (quantum dots, iron 
oxide nanoparticles, liposomes) (13, 17-22). The mechanism of this phenomenon is currently 
a subject of investigation, although important progress has been made, as some reports 
show that electrostatic interactions and hydrogen bonding lay behind certain proteins and 
peptides-mediated direct transduction of small molecules (23, 24), while the energy-
dependent macropinocytosis is responsible for certain proteins and peptides-mediated 
intracellular delivery of large molecules and nanoparticulates with their subsequent 
enhanced release from endosomes into the cell cytoplasm (25 – 28). 
One of the most outstanding achievements in the drug delivery field was the development 
of smart drug delivery systems (SDDSs), also called stimuli-sensitive delivery systems. The 
concept is based on rapid transitions of a physicochemical property of polymer systems 
upon a stimulus. This stimulus includes physical (temperature, mechanical stress, 
ultrasound, electricity, light), chemical (pH, ionic strength), or biological (enzymes, 
biomolecules) signals and such stimuli can either be internal, resulting from changes in the 
physiological condition of a living subject, or ‘‘external’’ signals, artificially induced to 
provoke desired events. SDDS provides a programmable and predictable drug release 
profile in response to various stimulation sources. Fig 1 below shows a typical smart drug 
delivery system; 
 
Figure 1. Smart drug delivery system -- Gold nanocage covered with polymer 
Depending on the desired applications, one may design different drug delivery systems for 
enhanced therapeutic efficiency with low systemic toxicity and side effects. SDDS has 
several advantages compared to conventional drug delivery systems. The conventional 
controlled release systems are based on the predetermined drug release rate irrespective of 
the environmental condition at the time of application. On the other hand, SDDS is based on 
the release-on-demand strategy, allowing a drug carrier to liberate a therapeutic drug only 
when it is required in response to a specific stimulation. The best example of SDDS has been 
self-regulated insulin delivery systems that can respond to changes in the environmental 
glucose level (29, 30). One of the most widely used SDDSs has been polymeric micelles. 
Many polymeric micelles consisting of hydrophobic and hydrophilic polymer blocks have 
been developed. They have been found to dissolve water-insoluble drugs, such as 
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doxorubicin or paclitaxel, at high concentrations. When administered to the body, drug 
release from polymeric micelles usually depends on simple diffusion, degradation of the 
micelle blocks, or disruption of the micelles by body components. 
The release kinetics of the loaded drug can be modulated by varying the degradation rate of 
hydrophobic polymer blocks, but because the degradation rate is usually very slow, the 
loaded drug is released by diffusion from polymeric micelles. This slow release by passive 
diffusion may not be desirable, as the polymeric micelles reaching the target site need to 
release their contents fast. To solve this problem, smart polymeric micelles have been 
designed to liberate the loaded therapeutic agent at the targeted site fast. For example, Lee 
et al, (31) reported that Poly (ethylene glycol)-b-polyhistidine (PEG-b-PHis) forms micelles 
only over the pKb of the polyhistidine block (pH 6.5–7.0). It is interesting to know that, the 
pKb can be adjusted by varying the molecular weight of polyhistidine. Since solid tumors 
have a slightly acidic environment, a small reduction in pH to less than 7 at the tumor site 
triggers dissociation of the polymeric micelle to release its contents. In a separate study, Lee 
et al (32) reported that, PEG-b- polyhistidine micelles containing doxorubicin effectively 
killed multi-drug resistant MCF-7 cells at pH 6.8. Similarly, Hruby et al, (33) reported that, 
SDDS can achieve a highly localized drug accumulation at target sites even though it is 
administered parenterally. It is therefore postulated that, SDDS with enhanced targeting 
property is highly promising in increasing the efficiency and efficacy of therapy while at the 
same time minimizing side effects. 
2.2. Polymer–drug conjugates 
Polymer–drug conjugates are a class of polymer therapeutics that consists of a water-soluble 
polymer that is chemically conjugated to a drug through a biodegradable linker. The idea 
started in 1975 when Ringsdorf proposed the use of polymer–drug conjugates to deliver 
hydrophobic small molecules (34). The reasoning was that, small molecule drugs, especially 
hydrophobic compounds, have a low aqueous solubility and a broad tissue distribution 
profile such that, administration of the free drug may result in serious side effects. 
Therefore, conjugation of these compounds to hydrophilic, biocompatible polymers would 
significantly increase their aqueous solubility, modify their tissue distribution profile and 
enhance their plasma circulation half-life. An important attribute of colloidal systems is their 
hydrodynamic diameter, which are typically about 3–20 nm for polymer–drug conjugates 
(35) and between 10 and 200 nm for colloidal particles such as micelles or liposomes. The 
colloidal nature or size of these vehicles can facilitate their retention within the circulation 
for prolonged periods, in comparison to low molecular weight small molecules. One major 
difference between polymer–drug conjugates and delivery systems that contain physically 
entrapped drug (e.g., micelles and liposomes) is that the drug is chemically conjugated to 
the polymer and therefore these systems qualify as new chemical entities (NCE). 
Classification as an NCE is often accompanied by additional development and regulatory 
hurdles that must be met in order to receive approval. Over the last decade, polymer-
conjugate technology has proven to be a viable formulation strategy. There have been 
reports (36 – 38) of bioconjugation of protein and peptide to PEG been able to significantly 
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improve the efficacy of these macro- molecular drugs by increasing their stability in the 
presence of proteases and decreasing their immunogenicity. Studies have also shown that 
by using PEG in a specific molecular weight range, the fast renal clearance and mononuclear 
phagocytic system uptake of the drugs can be prevented or delayed leading to a prolonged 
plasma half-life for the conjugated molecules. Successful applications have led to several 
FDA- approved products e.g. Neulasta®. The first practical use of polymer therapeutics that 
resulted in an FDA-approved anti-cancer treatment was the introduction of PEG-L-
asparaginase (Oncaspar1) in 1994. This conjugate is composed of PEG polymer (MW ~ 5 kD) 
attached to the enzyme, L-asparaginase, and is used for the treatment of acute 
lymphoblastic leukemia (39). In fact, polymer–drug conjugate itself can be considered as a 
nanovehicle. Various conjugates have been developed and clinically tested. Recent advances 
in polymer–drug conjugates are well described in reviews (Duncan, 2006; Duncan, Vicent, 
Greco, & Nicholson, 2005). One of the major advantages of polymer–drug conjugates is 
prolonged circulation in the blood stream by retarding degradation/metabolism/excretion 
rates of the conjugated drugs. Many peptide and protein drugs cannot be delivered by oral 
administration because of their large molecular weights. Even when administered directly 
into the blood stream, they do not remain in the blood for a long time due to fast 
degradation and metabolism, limiting the clinical applications. The circulation times of these 
drugs have increased substantially by conjugation with polymers, such as PEG. A good 
example is the glucagon-like peptide-1, which regulates food uptake and insulin release. 
The peptide is a very useful therapeutic agent for diabetic patients, but it is liable to 
degradation by a plasma enzyme, dipeptidyl dipeptidase IV, but by introducing one PEG 
chain, Lee et al (40) showed that its half-life could be increased up to 40 folds over the 
natural form. Very often, low molecular weight drugs with high hydrophobicity are used 
for conjugation with attendant reduction in the degradation/clearance rate as well as the 
toxicity of the conjugated drug. The therapeutic effect is achieved upon hydrolysis inside the 
target cells to release the original drug. The polymers used in conjugation usually have 
stimuli-responsiveness, imparting unique properties into the conjugated drug such that, its 
activities can be turned on or off by external signals. For example, Shimoboji et al, (41, 42) 
reported that, the catalytic activity endoglucanase 12A upon conjugation could be turned on 
by application of UV light or high temperature because, it was conjugated with either photo-
sensitive or thermo-sensitive polymers. The active site of the enzyme was exposed by 
collapsing the conjugated long polymer chain by external stimuli. Once visible light was 
turned on or the temperature was lowered, the enzyme activity vanished due to the 
blocking of the active site by the extended polymer chain. (43, 44) 
2.3. Multifunctional drug carriers 
A multifunctional drug delivery system (MDDS) refers to drug carrier that has multiple 
properties of prolonged blood circulation, passive or active localization at specific disease 
site, stimuli-sensitivity, ability to deliver drug into intracellular target organelles, and/or 
imaging ability (45). Technically therefore, it has two or more functions, infact, SDDS and 
polymer–drug conjugates discussed above can be considered MDDS. In addition to 
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delivering drugs, MDDS can carry out the second function, such as stimuli-responsiveness 
or hydrolysis inside cells. Some reported MDDS include the biotin-tagged pH-sensitive 
polymeric micelles based on a mixture of PLA-b-PEG-b-PHis-biotin (PLA=poly (L-lactic 
acid)) and PEG-b-PHis block copolymers by Lee et al (46) in which the targeting moiety, 
biotin, was masked until the carrier was exposed to an expected environment of pH 7.0. 
Once the nanocarrier was internalized to cancer cells by ligand– receptor interactions, 
lowered pH (< 6.5) destabilized the carrier resulting in a burst release of the loaded drug 
and that of Lukyanov et al (47), where a pH-degradable PEG-b-phosphatidylethanolamine 
(PE) liposome had anti-myosin monoclonal antibody as well as TAT or biotin attached on its 
surface. 
2.4. Organic/inorganic composites 
An inorganic-organic composite usually comprises an inorganic phase and a film forming 
organic phase. A typical green approach to developing an inorganic-organic composite 
involves the selection of film forming organic phase from starches having a degree of 
polymerization; degree of substitution and viscosity such that the substituted starches are 
insoluble in water during mixing but dissolve at a higher processing temperature during 
forming, setting or drying of the composite. Thus, excessive migration of the starch is 
prevented and the composite is substantially strengthened. There has also been reports on 
the lab-on-a-chip approach (48 – 54), which embodies micron- or nano-sized machines 
composed of sophisticated circuits. Small devices have many advantages including 
portability/disposability, low cost, high reproducibility, high-throughput screening, and 
multiple functionalities in a single device. Recently, combined with other technologies such 
as optics, single molecular imaging, or cell/protein-based assay systems, biomedical lab-on-
a-chip devices have become an important part of drug discovery and diagnosis, but its 
application in drug delivery systems based on are just beginning to appear (55 – 57).  
As rightly noted by several authors, to release a drug from a nanodevice is more 
complicated than to perform assay or screening drug candidates, this is because, successful 
drug delivery requires at least four components namely; drug reservoir, pump, valve, and 
sensor (58). Drugs can be placed either in a fabricated reservoir or in conventional micro-
/nanoparticles. Other important organic/inorganic composites are metal nanoparticles, such 
as silver, iron oxide, or gold nanoparticles, coated with hydrophilic polymers. Their major 
application has been as theranostics. Only recently, Hirsch et al, (59) developed gold 
nanoshell, which provided tunable emission light for bioimaging. Importantly, is the fact 
that, gold nanoparticles can be detected by X-ray and emit thermal energy by excitation 
making it very useful for medical imaging and thermal therapy (theranostics). In a related 
report, Corot et al, (60) developed super paramagnetic iron oxide nanoparticles for magnetic 
resonance imaging (MRI) of the whole body. Mechanistically, these nanoparticles are 
primarily engulfed by monocyte or macrophage after intravenous administration. However, 
uptake of super paramagnetic iron oxide by macrophage does not induce activation of 
nearby cells making it suitable for diagnosis of inflammatory or degenerative diseases.  
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3. Nanoparticulate drug delivery systems 
3.1. Liposomes 
Use of micro and nano particles in biomedicine and especially in drug delivery has a great 
deal of advantages over conventional systems such as: the enhanced delivery, high 
performance characteristics of the product, use of lesser amounts of expensive drugs in the 
delivery systems, extension of the bioactivity of the drug by protecting it from 
environmental effects in biological media, more effective treatment with minimal side 
effects. In addition, research for the design of more effective delivery systems is more 
economical for the discovery of a new bioactive molecule. Micro and nano colloidal drug 
delivery systems such as emulsions, suspensions and liposomes have been used for decades 
for this purpose and recently, nanosized systems with dimension of less than 100 nm gained 
significant attention. Nanotechnology promises to generate a library of sophisticated drug 
delivery systems that integrate molecular recognition, diagnostic and feedback. 
Nanotechnology is expected to create lots of innovations and play a critical role in various 
biomedical applications including the design of drug and gene delivery systems, molecular 
imaging, biomarkers and biosensors. By understanding the signaling and interaction 
between the molecules at nano levels, it would be possible to mimic biological systems. 
Liposomes are small spherical vesicles (Fig. 2) in which one or more aqueous compartments 
are completely enclosed by molecules that have hydrophilic and hydrophobic functionality. 
Liposomes vary with composition, size, surface charge and method of preparation. They can 
be single or in multiple bilayers. Those containing one bilayer membrane are termed small 
unilamellar vesicles or large unilamellar vesicles based on their sizes (61). If more than one 
bilayer is present then they are called multilamellar vesicles. Liposomes are commonly used 
as model cells or carriers for various bioactive agents including drugs, vaccines, cosmetics 
and nutraceuticals. Drugs associated with liposomes have markedly altered 
pharmacokinetic properties compared to free drugs in solution. Liposomes are also effective 
in reducing systemic toxicity and preventing early degradation of the encapsulated drug 
after administration. They can be covered with polymers such as polyethylene glycol (PEG) 
– in which case they are called pegylated or stealth liposomes, in this form, they usually will 
exhibit prolonged half-life in blood circulation. Liposomes can also be conjugated to 
antibodies or ligands to in order enhance target-specificity. For example, Visser et al (62) 
studied pegylated horse –radish-peroxidase loaded liposomes, tagged with transferrin to the 
blood-brain barrier. The authors showed an effective targeting of liposomes loaded with 
protein or peptides to the brain capillary endothelial cells and suggested that the system 
could be an attractive approach for targeting drug delivery to brain. In another report, 
Lopez-Pinto and coworkers (63) examined the dermal delivery of a lipophilic drug, 
minoxidil, from ethosomes versus classic liposomes by applying the vesicles non-occlusively 
on rat skin, yet in a separate study, Ozden and Hasirci (64) prepared small unilamellar 
vesicles composed of phosphatidyl- choline, dicetyl phosphate and cholesterol and 
entrapped glucose oxidase in them. Liposomes are also studied as carriers for cells, genes or 
DNA fragments. Ito et al (65) studied the effect of magnetite cationic liposomes which have 
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positive surface charge to enrich and proliferate Mesenchymal stem cells (MSCs) in vitro. 
Kunisawa et al (66) established a protocol for the encapsulation of nanoparticles in 
liposomes, which were further fused with ultra violet-inactivated Sendai virus to compose 
fusogenic liposomes and observed that fusogenic liposome demonstrated a high ability to 
deliver nanoparticles containing DNA into cytoplasm.  
Foco et al (67) studied the delivery of sodium ascorbyl phosphate (SAP), an effective oxygen 
species scavenger to prevent the degenerative effects of UV radiation on skin. SAP was 
encapsulated into liposomes to improve its penetration through the stratum corneum into 
the deeper layers of the skin. Sinico et al (68) studied transdermal delivery of tretinoin and 
examined the influence of liposome composition, size, lamellarity and charge on 
transdermal delivery. They studied positively or negatively charged liposomes of different 
types. It was reported that negatively charged liposomes strongly improved newborn pig 
skin hydration and tretinoin retention. Arcon et al (69) encapsulated an anticancer agent, 
cisplatin, in sterically stabilized liposomes and studied the systems with extended X-ray 
absorption fine structure method, and concluded that the liposome-encapsulated drug is 
chemically stable and does not hydrolyze.  
– Spherical vesicles with a phospholipid bilayer
Hydrophilic
Hydrophobic
 
Figure 2. Spherical vesicles with a phospholipid bilayer 
 
Figure 3. Cell Membrane 
 
Figure 4. Modes of Liposome/Cell Interaction 
Adsorption Endocytosis
Fusion Lipid transfer
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Conventional Long circulating 
Immuno Cationic
 
Figure 5. Classes of Liposomes 
Type of Agents Examples
Anticancer Drugs
Anti bacterial
Antiviral
DNA material
Enzymes
Radionuclide
Fungicides
Vaccines 
*Currently in Clinical Trials or Approved for Clinical Use
Malaria merozoite, Malaria sporozoite
Hepatitis B antigen, Rabies virus glycoprotein
Amphotericin B*
In-111*, Tc-99m
Hexosaminidase A 
Glucocerebrosidase, Peroxidase
Duanorubicin, Doxorubicin*, Epirubicin 
Methotrexate, Cisplatin*, Cytarabin
Triclosan, Clindamycin hydrochloride, 
Ampicillin, peperacillin, rifamicin
AZT
cDNA - CFTR*
 
Source: Jessica Scott, www.nanobiotec.iqm.unicamp.br 
Table 1. Current liposomal drug preparations      
3.2. Microemulsions 
Microemulsions are isotropic, thermodynamically stable systems composed of oil, water, 
and surfactant.  Thermodynamic stability rather than size, is the defining hallmark of a 
microemulsion, although the droplet sizes are still below 100 nm (and many times much 
smaller) (70). Be that as it may, what is critical about microemulsions is that, they contain 
two phases consisting of two immiscible liquids that are mixed together and stabilized with 
the aid of a surfactant with or without a co-surfactant. They may have droplets in the range  
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Liposome Utility Current Applications Disease States Treated 
Solubilization 
 
Site-Avoidance 
 
 
 
 
Sustained-Release 
 
 
 
Drug protection 
 
RES Targeting 
 
 
 
Specific Targeting 
 
 
Extravasation 
 
 
Accumulation  
Amphotericin B, minoxidil 
 
Amphotericin B – reduced 
nephrotoxicity 
doxorubicin – decreased cardiotoxicity 
 
 
Systemic antineoplastic drugs, 
hormones,  corticosteroids, drug depot in 
the lungs 
 
Cytosine arabinoside, interleukins 
 
Immunomodulators,vaccines,  
antimalarials,macophage-located 
diseases 
 
Cells bearing specific antigens    
 
 
Leaky vasculature of tumors, 
inflammations, infections 
 
Prostaglandins
Fungal infections 
 
Fungal infections, cancer 
 
 
 
 
Cancer, biotherapeutics 
 
 
 
Cancer, etc. 
 
Cancer, MAI, tropical parasites 
 
 
 
Wide therapeutic applicability 
 
 
Cancer, bacterial infections 
 
 
Cardiovascular diseases 
Source: Handbook of Biological Physics Volume 1, (ed. R. Lipowsky and E. Sackmann). Elsevier Science B. V. 
Table 2. Some applications of liposomes in the pharmaceutical industry 
of 5–100 nm. The difference between microemulsions and emulsions is that, the later are 
opaque mixtures of two immiscible liquids, thermo- dynamically unstable and usually 
require the application of high torque mechanical mixing or homogenization to produce 
dispersed droplets in the range of 0.2–25 mm. Both types can be made as water-in-oil (w/o) 
or oil-in-water (o/w) (70). Choice of the dispersed and continuous phases for 
microemulsions formulations is based on the hydrophilicity of the model drug. Also, 
surfactants that have hydrophilic–lipophilic balances (HLB) of 3–6 tend to promote the 
formation of w/o microemulsions while those with HLB values of 8–10 tend to promote the 
formation of o/w microemulsions. It has been reported (70) that, the formation and stability 
of microemulsions are dependent on the interfacial tension between the dispersed and 
continuous phases. Microemulsion instability can lead to Oswald ripening leading to 
dissolution of the small droplets with a resultant increase in the size of the large droplets, 
therefore, stabilization against Ostwald ripening is very critical, this is because, the resultant 
change in the size of the droplets could lead to loss of physical stability of the dosage form. 
Choice of the components of microemulsions affects its stability (70). Safety is also another 
important factor that must be considered during component selection. Attwood, 1994 had 
opined that, the irritant and toxic properties of some alcohols (1-butanol and 2-butanol) 
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could limit their potential use. Microemulsions have been proposed as drug delivery 
systems to enhance the absorption of drug across biological membranes (70). Some of the 
advantages of microemulsions include (i) Increased solubility and stability of drugs (ii) ease 
and economy of scale-up. Some of the disadvantages are; (a) premature leakage/release of 
incorporated drug (b) phase inversion (c) Many of the effective surfactants and/or co-
surfactants do not have a pharmaceutically acceptable toxicity profile; and (d) 
microemulsion systems often require development of complex systems that may be time 
consuming.  
Product Developed Applications
Rapamune® Elan’s An immunosuppressant
Emend® Elan’s Anti-nausea
Estrasorb® Elan’s Topical estrogen therapy
Megace® ES Elan’s Stimulate appetite
TriCor® Elan’s Cholesterol-lowering
Abraxane® APP Breast cancer
Doxil® Alza Anti-cancer
Acticoat® Smith & Nephew Antimicrobial
SilvaGard AcryMed, Inc., Antimicrobial
 
Source: B. K. Nanjwade, Department of Pharmaceutics, KLE University College of Pharmacy, BELGAUM-590010 
Table 3. Some medical applications of liposomes  
3.3. Nanoparticles 
Nanoparticle drug delivery systems are nanometeric carriers used to deliver drugs or 
biomolecules. Generally, nanometeric carriers also comprise sub-micron particles with size 
below 1000 nm and with various morphologies, including nanospheres, nanocapsules, 
nano- micelles, nanoliposomes, and nanodrugs, etc. (71, 72). Nanoparticle drug delivery 
systems have outstanding advantages, some of which include; (1) they can pass through the 
smallest capillary vessels because of their ultra-tiny volume and avoid rapid clearance by 
phagocytes so that their duration in blood stream is greatly prolonged; (2) they can 
penetrate cells and tissue gap to arrive at target organs such as liver, spleen, lung, spinal 
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cord and lymph; (3) they could show controlled- release properties due to the 
biodegradability, pH, ion and/or temperature sensibility of materials; (4) they can improve 
the utility of drugs and reduce toxic side effects. As drug delivery system, nanoparticles can 
entrap drugs or biomolecules into their interior structures and/or absorb drugs or 
biomolecules onto their exterior surfaces. Presently, nanoparticles have been widely used to 
deliver drugs, polypeptides, proteins, vaccines, nucleic acids, genes and so on. Over the 
years, nanoparticle drug delivery systems have shown huge potential in biological, medical 
and pharmaceutical applications (73). Currently, the researches on nanoparticle drug 
delivery system focus on: (1) the selectness and combination of carrier materials to obtain 
suitable drug release speed; (2) the surface modification of nanoparticles to improve their 
targeting ability; (3) the optimization of the preparation of nanoparticles to increase their 
drug delivery capability, their application in clinics and the possibility of industrial 
production; (4) the investigation of in vivo dynamic process to disclose the interaction of 
nanoparticles with blood and targeting tissues and organs, etc. One type of nanoparticle, 
which is differentiated from any of the above terms, is a solid lipid nanoparticle (SLN) with 
a lipid core that is solid at room temperature. During formation of SLNs the solid lipid is 
first melted, then emulsified as a liquid to form an o/w emulsion, and cooled to allow the 
lipid to solidify. Due to the similarity in formation and content, these particles have been 
referred to as ‘‘emulsions with solid fat globules’’.  
TEM (a, b, and c) images of prepared mesoporous silica nanoparticles with mean outer 
diameter: (a) 20nm, (b) 45nm, and (c) 80nm. SEM (d) image corresponding to (b). The insets are 
a high magnification of mesoporous silica particle
 
Source: B. K. Nanjwade api.ning.com/.../DevelopmentofNanotechnologyBasedDrugsanditsGu 
Figure 6. Transmission and electron micrographs of silica nanopartcles   
Nanoparticles are solid colloidal particles, ranging in size from 1 to 1000 nm, consisting of 
various macromolecules in which the therapeutic drugs can be adsorbed, entrapped or 
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covalently attached. The distinct advantages offered by solid nanoparticles in drug 
development can be ascribed to their physical stability and the possibility of modifying the 
formulating materials in order to achieve controlled release characteristics. The ability to 
formulate nanoparticles to achieve sustained release offers an opportunity for product life 
cycle management by developing formulations with decreased dosing frequency for drugs 
that are going off patent. There has been a variety of materials used to engineer solid 
nanoparticles both with and without surface functionality. Perhaps the most widely used 
are the aliphatic polyesters such as poly (lactic acid) (PLA), the more hydrophilic poly 
(glycolic acid) (PGA) and their copolymers poly (lactide-coglycolide) (PLGA). The 
degradation rate of these polymers and often the corresponding drug release rate can vary 
from days (PGA) to months (PLA). The effectiveness of nanoparticles in drug delivery can 
be attributed to many factors such as physical and biological stability, good tolerability of 
the components, simplicity of the manufacturing process, possibility of facile scale-up of the 
manufacturing process, amenability to freeze drying and sterilization.  
4. Some natural polymers in nanodrug delivery 
4.1. Starch 
Starch is a common polysaccharide. It occurs majorly in plants where they act as storage 
materials. Chemically, it is composed of recurring units of glycopyranose in an alpha D-(1, 
4) linkage and on hydrolysis yields the monosaccharide, glucose (Heller et al., 1990). The use 
of starch in pharmaceutics is extensive. It is used as co-polymer and excipient in controlled 
drug delivery (74 – 76) as drug carriers in tissue engineering scaffolds (77) as Hydrogels (78) 
and as solubility enhancers (79). 
Santander-Ortega et al. (80) investigated the potential of starch nano-particles as a transdermal 
drug delivery system (TDDS). The challenge faced in delivering drug through these systems is 
that the skin acts as an effective barrier to drug passage and must therefore be overcome for 
effective drug delivery. Nano-particles were shown to facilitate drug delivery without 
interference to the skin’s integrity. The method used to prepare the nano-particles was 
emulsification-diffusion due to its reproducibility, higher yields, ease of scale-up and control 
over size of particles and degree of polydispersity. Maize starch modified and un-modified (by 
the addition of propyl groups) was used as polymeric material to formulate 2 different types of 
nano-particles. The modified starch nano-particles were shown to be non-toxic using LDH 
(Lactose dehydrogenase) and MTT assay and resulted in particles of uniform size distribution 
while the nano- particles formulated from the native starch was not observable. Flufenamic 
acid, caffeine and testosterone were used as model drugs and their delivery across the skin 
was analyzed using excised skin from female Caucasian patients who had undergone 
abdominal plastic surgery. Permeation data obtained for caffeine and testosterone were similar 
for nano-encapsulated and free drugs while the delivery of flufenamic acid using the nano-
particles was enhanced by about ten-fold.  
Starch nano-particles have been employed to deliver insulin via non-invasive routes; 
Makham (81) investigated the use of chitosan cross linked starch polymers as carriers for 
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oral insulin delivery, manipulating the bio-adhesive and not so adhesive properties of 
chitosan and carboxymethyl starch to formulate hydrogels loaded with insulin. The authors 
however noted that, Insulin delivered by this method however faces the challenge of being 
broken down by proteases.  
The nasal route can also be considered as an alternative to the subcutaneous route of 
administration because it is highly vascularised and is of great benefit in drug delivery as 
drugs given through this route are not subject to first-pass metabolism. However for 
effective delivery through this route, it is crucial that barriers to nasal drug delivery which 
include the lipophilic epithelium and muco-ciliary clearance must be overcome.  Jain et al., 
(82) reports a size dependent insulin release in rats from starch nano-particles.  Potato starch 
was used to prepare 2 differents types of nano-particles by cross-linking with 
epichlorohydrin and phosphoryl chloride (POCl3) using both the gel and emulsion methods. 
These methods however led to the production of polydispersed nano-particles. There were 
statistically significant differences in mean sizes except in emulsion prepared 
epichlorohydrin cross linked particles which were smaller and of uniform distribution. In-
vitro studies showed that drug release followed first order kinetics and was diffusion 
controlled along with burst effect, due to the presence of left-over insulin on the surface of 
the nanopartices after entrapment. Emulsion cross-linked particles released their drug faster 
than gel cross linked particles with 85-90% and 81% release in 12 hrs respectively. These 
differences were attributed to the diffusion path length of the drug within the particles. The 
smaller the particle size the less distance the drug will travel to be released.  Tests carried 
out on the diabetes induced rats showed a 50-65% reduction in blood glucose by nano-
particles compared to plain insulin formulation which served as control and this lasted for 
about 6hrs. Permeation enhancers modulated the hypoglycaemic effect and bioavailability 
of nano-particles, Plasma insulin levels of small sized nano-particles were also found to be 
significantly higher. Conclusions obtained from the study however recommend that further 
work would be needed in order to produce a more efficient carrier system.   
Simi and Abraham (83) note that the presence of hydroxyl groups on starch enhances its 
hydrophilicity and confers on it low moisture resistance. This property poses a major 
constraint in drug delivery as a result of which it is often necessary to modify the polymer 
before it is made into nano particles as observed above. In their study, starch extracted from 
cassava tuber was modified by graft co-polymerization using long chain fatty acids before 
the resulting polymer was made into nano-particles (83). The nano-particles were prepared 
by dialysis and subsequently crosslinked using sodium tripolyphosphate. Oleic acid and 
stearic acid were both used as fatty acids while indomethacin was used as model drug. 
Findings showed that drug release from both types of nano-particles was effectively 
controlled. It is however not clear whether there was a significant difference between drug 
releases in both types of nano-particles. No attempts were also made to formulate the un-
modified starch granules into nano-particles though this may have been due to results 
obtained from differential scanning calorimetry which showed that native starch was less 
processable than grafted starch. 
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In addition, magnetised iron-oxide nano-particles coated with starch were used by Cole et 
al. (84) as a means of targeting brain tumours. Magnetic resonance imaging and histological 
reports showed that surface modification with polyethylene oxide improved delivery to 
tumour cells resulting in a greater accumulation of particles in the glioma compared to the 
rest of the brain.   
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Figure 7. Granule structure of some common native starches 
4.2. Chitosan 
This polymer is obtained from the partial N-deacetylation of chitin found in the shells of 
crustacean. It is composed of glucosamine and N-acetyl glucosamine linked by β 1-4 
glucosidic bonds and is one of the most widely studied natural polymers for nano-drug 
delivery. The deacetylation of chitin is both concentration and temperature dependent with 
optimal yields achieved at temperatures between 600C- 800C using 50%w/w alkali (85).                             
Park et al.,(86) in a review on chitosan describes its numerous applications in delivering low 
molecular weight drugs and summarises the reason for its choice being in its 
physiochemical and biological properties, enabling chemical modification and enhanced 
residence time respectively. It has been used    as both a composite membrane with collagen 
(87) and a cross linked polymer for transdermal delivery of   propranolol (88). 
Nano-particles fabricated with chitosan as co-polymer was used to by Dev et al., (89) to 
investigate the controlled release of anti-retroviral drug, lamivudine.  The nano-particles 
were prepared by emulsion and solvent evaporation technique and characterised using 
dynamic light scattering.  The use of this method resulted in monodispersed particles with a 
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size range of 300-350nm. Two formulations with differences in percentage drug weight (3% 
and 6%) were made, of which drug release rate was higher from the nano-particles with 
higher drug loading, though both were able to control drug release fairly well. Drug release 
kinetics showed that the mechanism of drug release was by diffusion. Conclusions reached 
suggested that the nano-particles could be applied for gastrointestinal drug delivery 
because drug release was relatively slower at neutral pH compared to acidic pH and also 
slower in the acidic pH compare to the alkaline pH. 
Chitosan combination was also used by Menon et al. (90) for therapeutic drug delivery. 
Nano-complexes of chitosan and polyoxometalates (POM) were tested as anti-cancer 
preparation. Since POM’s though toxic have shown promise in being used as anti- viral and 
anti-tumour agent, the role of chitosan was to minimise the toxicity associated with POM, 
by modifying its surface properties. Mono-dispersed particles with size 200nm were 
produced using ionotropic gelation technique and the use of probe sonication was shown to 
control particle size and distribution compared to ultrasonication. In-vitro studies showed 
that the nano-complex was able to sustain drug release with enhanced anti-tumour activity 
at much lesser doses than the POM alone. 
Similarly as with starch nano particles, Luo et al. (91) used chitosan oligosaccharides 
(COS) to coat lipid based carriers in order to enhance ocular drug delivery. This material 
is obtained from the decomposition of chitosan, but it is more soluble in water than chitin 
and chitosan. Drug introduced into the eye have minimal residence times as they are 
quickly washed away and have to be re-administered regularly. But in this study, COS 
enhanced permeation and adhesion of the cornea. There was a 7.7 fold and 2.8 fold 
retention of the model drug, flubiprofen by the COS coated nano lipid carriers compared 
to the phosphate buffer solution and uncoated nanolipid carriers which were attributed to 
the mucoadhesive properties of COS. The use of COS was also found to be non-irritating 
to the eye, a property which is of utmost importance in the choice of a suitable eye 
formulation. 
4.3. Gelatin   
Gelatin is obtained from the breakdown and hydrolysis of collagen, obtained from the 
connective tissues, bones and skins of animals. It is a known matrixing agent drug 
delivery. Bajpai and Shoubey (92) describes a process for the controlled release of 
sulphamethoxazole using 2 different gelatin nano-particles {Type A (porcine skin) and 
type B gelatin( bovine skin)} and cross linked with gluteraldehyde;  Nano-particles of 
varying gelatin concentrations were prepared by solvent evaporation techniques and drug 
release kinetics evaluated using appropriate kinetic models. Findings from this system 
suggest that this system could be of use in targeted drug delivery such as colon drug 
delivery where pH is an important consideration. Drug release was found to increase 
following increased swelling of the nanoparticles. In addition, swelling was further 
enhanced by an increase in pH with greater drug release occuring at pH 7.5 than at pH 
1.8. The nano particles were also not degraded in simulated gastric fluid thereby showing 
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their stability under acidic conditions. An increase in concentration of the cross linker led 
to an increase in swelling and drug release up until a certain concentration(10.6mM) when 
swelling began to decline. This relationship between the amount of cross linker and the 
polymer has also been reported by Das et al. (93); In their case, nano-particles composed 
of gelatin blended with montmorillonite (MMT) were loaded with the anti-cancer agent 
paclitaxel. These nano-particles were prepared by the same method of solvent 
evaporation and produced similar results. Increase in gluteraldehyde concentrations was 
reported to increase swelling and consequently drug release up until a certain point, 
when further increases in concentration of the cross linker led to decreased swelling and 
drug release. There was also a cumulative increase in drug release with increased pH. 80% 
of the drug was released within 8hrs at pH 7.4 while there was less than 44% drug release 
within 4 h at pH 1.2. Increasing concentration of the loaded drug also led to an increase in 
drug release.   
The use of proteins as nano carriers is also employed in gene therapy. Viral and non-viral 
vectors are used for the transfection of DNA into cells, because, the injection of naked DNA 
into living tissue results in enzymatic degradation and reduced cellular uptake due to 
repulsion between the negatively charged DNA and cell membrane. In this domain, Coester 
et al., (94) used avidin modified gelatin nano-particles for the delivery of   biotinylated PNA 
(Peptide nucleic acids) in other to investigate their use as anti-sense therapy. Zwiorek et al. 
(95) suggests that gelatin nano- particles have the potential to be used for effective non-viral 
gene delivery and are a safer alternative to the use of viral vectors. A 2 step desolvation 
process was used to prepare cationized particles of uniform size distribution and low 
polydispersity and comparisons between polyethyleneimine- DNA complexes and the 
gelatin particles showed that the latter is effective in facilitating gene expression, has less 
toxic and better tolerated.  
Transfection with the aid of gelatin nanoparticles was also used by Xu et al. (96) for the 
delivery of DNA plasmids encoding for insulin growth like factor 1(IGF-1) into 
chrondrocytes. In order to incorporate the plasmids into the gelatin nano-particles, complex 
coacervation was employed because it is an easy, fast and particularly useful method for the 
incorporation of large molecules. The authors proved that, cationized gelatin particles were 
of smaller sizes than non- cationized particles, this they attributed to the condensation of the 
cationized particles. Fluorescence spectroscopy showed that the cationized gelatin nano-
particles were successfully transfected and expressed the gene while the reverse was the 
case for the non-cationized gelatin particles. This is probably due to enhanced endocytosis, 
occurring as a result of interactions between the positive charge on the former and the 
negative charge on the cell membrane. A 5-fold increase in growth factor production was 
observed in cells containing these nano-particles. Findings also showed that over expression 
of the gene was maintained steadily for up to 2 weeks when they were grown in collagen 
(type II) -glycosaminoglycan scaffolds in 3D culture. Since a prolonged and localized release 
of IGF-1 was achieved in this study, and IGF-1 is known to promote growth in skeletal 
muscle, cartilage and bones and numerous other tissues in the body tissue,   this approach 
shows potential applications in gene therapy and tissue engineering.   
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5. Properties of nanoparticles 
Some of the properties of nanoparticles that are important for application in drug delivery 
include simple, affordable manufacturing process that is easy to scale up. The 
manufacturing process excludes organic solvents or potentially toxic ingredients. All the 
components of the formulation should be commercially available, safe, affordable, non-toxic 
and biodegradable. The nanoparticles should be stable with respect to size, surface 
morphology, size distribution and other important physical and chemical properties. 
6. Preparation of nanoparticles  
6.1. Nanosuspensions 
Nanosuspension refers to production of sub-micron-sized particles by subjecting the 
combination of drug and a suitable emulsifier to the process of milling or high-pressure 
homogenization. Conventional milling and precipitation processes generally result in 
particles with sizes that are much greater than 1 mm. As such, a critical step in the 
nanosuspension preparation is the choice of the manufacturing procedure to ensure 
production of sub-micron particles.  Nanosuspension formulations can be used to improve 
the solubility of poorly soluble drugs. A large number of new drug candidates emerging 
from drug discovery programs are water insoluble, and therefore poorly bioavailable, 
leading to abandoned development efforts. These can now be rescued by formulating them 
into crystalline nanosuspensions. Techniques such as media milling and high-pressure 
homogenization have been used commercially for producing nanosuspensions. The unique 
features of nanosuspensions have enabled their use in various dosage forms, including 
specialized delivery systems such as mucoadhesive hydrogels. Nanosuspensions can be 
delivered by parenteral, per- oral, ocular, and pulmonary routes. Currently, efforts are being 
directed to extending their applications in site-specific drug delivery. Various particle sizes 
of spironolactone, a model low solubility drug, have been formulated to yield micro- and 
nanosuspensions of the type solid lipid nanoparticles and DissoCubes. The DissoCubes 
nanosuspension yielded highly significant improvements in bioavailability. Particle size 
minimization is not the major determining factor in the bioavailability improvement. Rather, 
the type of surfactant used as stabilizer in the formulations is of greater importance. 
Improvement in drug solubility in the intestine as well as in dissolution rate of 
spironolactone is the most likely mechanisms responsible for the observed effect, although 
additional mechanisms such as permeability enhancement may also be involved. 
Development of nanoparticle formulations for improved absorption of insoluble 
compounds and macromolecules enables improved bioavailability and release (97)  
Particle size reduction to sizes below 1 mm is usually difficult due to possible particle 
aggregation and generation of high surface area materials. Milling techniques that have 
been used to generate nano-sized particles are ball milling or pearl milling that applies 
milling beads of sizes ranging from 0.4 to 3 mm and these beads may be composed of glass, 
ceramics or plastics (98). The time required for milling depends on the hardness and 
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brittleness of the drug material in comparison to milling material and inertial forces set up 
within the mill. Some of the challenges that milling processes can pose in drug development 
are (i) undesirable erosion of the milling equipment components into the drug product; (ii) 
the process is usually time consuming, thereby prolonging drug development time; (iii) 
milling over a few days may bring the risk of microbiological problems or increases in the 
cost of production; also (iv) prolonged milling may induce the formation of amorphous 
domains in crystalline starting materials or may lead to changes in the polymorphic form of 
the drug. The generation of amorphous form of the drug is problematic because these forms 
may crystallize during the shelf life of the drug leading to changes in solubility and 
bioavailability of the drug. An example of the conversion of crystalline to amorphous form 
of the drug was observed in jet milling of albuterol sulfate. Also, the generation of high-
energy surfaces that affected wettability was observed with acetylsalicylic acid. Some 
examples of nano-sized particles produced by milling as reviewed by Majuru and Oyewumi 
(70) are (i) naproxen nanoparticles approximately 200 nm in diameter and (ii) danazol 
particles of a mean size of 169 nm. The authors also reported that, there were four approved 
drug products in the USA that are based on NanoCrystal technology: (a) Rapamune 
(sirolimus) tablets by Wyeth; (b) Tricor (fenofibrate) tablets by Abbott; (c) Emend 
(aprepitant) capsules by Merck; and (d) Megace ES (megestrol) oral suspension by Par 
Pharmaceuticals (70). High pressure homogenization has also been recognized as an 
effective method of producing nanosuspensions (98). Again, Majuru and Oyewumi (70) 
reported that, high-pressure homogenization has been applied commercially with the 
development of some drug products, such as fenofibrate and paclitaxel. A typical procedure 
for preparing nanosuspension involves, preparing an aqueous suspension of drug in 
surfactant solution, this is then passed through a high pressure of typically 1500 bar at 3–20 
homogenization cycles. The suspension is then passed through a small gap in the 
homogenizer of typical width 25 mm at 1500 bar. Due to built up cavitation forces that are 
created drug particles are broken down from micro to nanoparticles. An example is in the 
micro fluidization of atovaquone to obtain particles in the 100–300 nm size range Majuru 
and Oyewumi (70). It has been reported that, nanosuspension particles in most cases have 
an average size ranging from 40 to 500 nm with a small (0.1%) proportion of particles larger 
than 5 mm Majuru and Oyewumi (70).  Experts have recognized that, a major challenge in 
the use of high-pressure homogenization is the possible changes in drug crystal structure 
that may cause batch-to-batch variation in crystallinity level, and have suggested that, 
application in drug delivery should include the desired specification by which the quality of 
each batch will be evaluated.  
6.2. Polymeric nanoparticles 
Polymeric nanoparticles can be identified as submicronic (size< 1µm) colloidal carriers. 
Compared to other colloidal carriers polymeric Nanoparticles hold significant promise for 
the advancement of treating diseases and disorders. They have attractive physicochemical 
properties such as size, surface potential, hydrophilic-hydrophobic balance and for this 
reason they have been recognized as potential drug carriers for bioactive ingredients such as 
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anticancer drugs, vaccines, oligonucleotides , peptides, etc. Their widespread use for oral 
delivery also aims at improving the bioavailability of drugs with poor absorption 
characteristic, reducing GI mucosa irritation caused by drugs and assuring stability of drugs 
in the GI tract. Thus, all these and many more such characteristics of nanoparticles qualify 
them as a promising candidate in drug-delivery technology. Although various 
biodegradable nanoparticles of natural polymers such as starch, chitosan, liposomes etc, are 
largely in use as drug carriers in con- trolled Drug-delivery technology (99). Many FDA-
approved biodegradable and biocompatible polymers have been used in nanoparticle 
preparation. These include polylactide-polyglycolide copolymers, polyacrylates and 
polycaprolactones. Nanoparticles can be prepared from polymerization of monomers or 
from preformed polymer with the possibility of performing many chemical modifications. 
The polymerization reaction in these systems generally occurs in two steps: a nucleation 
phase followed by a growth phase and the process can be carried out in two ways either as 
emulsion polymerization or as interfacial polymerization. When nanoparticle preparation 
involves polymerization, it is undesirable to have residual monomers and initiators in the 
final nanoparticle formulation. A critical step of the process is the purification and removal 
of residual monomers. It is also very important to separate free drugs from the drug loaded 
nanoparticle suspension. A potential challenge for polymeric nanoparticles is associated 
with residues from organic solvents and polymer toxicity. If the drug to be incorporated in 
nanoparticles is hydrophobic, the drug is dissolved or dispersed into the polymer solution. 
The polymer solution is then added to an aqueous solution, followed by high-speed 
homogenization or sonication to form an oil-in-water emulsion. Nanoparticle preparation is 
usually facilitated and stabilized with the aid of an emulsifier or stabilizer. If the drug to be 
incorporated in nanoparticles is hydrophilic, the drug is added to the aqueous phase and 
entrapped into nanoparticles through a double emulsification method to form water-in-oil-
in-water emulsion Majuru and Oyewumi (70). Residual organic solvent can be removed by 
evaporation or a decreased pressure or under a vacuum environment with or without the 
aid of inert gas flow. Solid nanoparticles are cured from the suspension by centrifugation, 
filtration or freeze drying. Another method is based on particle precipitation upon addition 
of a non-solvent to polymer solution under mechanical stirring. This method allows the 
formation of nanoparticles without prior emulsification. Nanoparticle formation and 
characteristics are dependent on the choice of the polymer/solvent/non-solvent system that 
will ensure mutual miscibility of the solvent and non-solvent of the polymer, Majuru and 
Oyewumi (70). Nanoparticles can also be prepared from natural macromolecules using 
methods such as thermal denaturation of proteins (such as albumin) or gelification process 
such as in alginates. In general, the controlling factors in the nanoparticle formulation 
process, which are adjustable for an ideal design, are the polymer type and its molecular 
weight, the copolymer blend ratio, the type of organic solvent, the drug loading level, the 
emulsifier/stabilizer and oil–water phase ratio, the mechanical strength of mixing, the 
temperature and the pH. These authors have opined that, in production of a drug product it 
is important to set a limit for residual solvent in the formulation that is based on the 
acceptable daily intake and to develop analytical methods for testing of the solvent levels in 
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the nanoparticles. Table 4 below shows some of the applications of polymeric materials in 
nanodrug delivery. 
 
 
Source: B. K. Nanjwade api.ning.com/.../DevelopmentofNanotechnologyBasedDrugsanditsGu 
Table 4. Polymer colloids for nanodrug delivery 
6.3. Polymers for gene delivery 
The delivery of nucleic acid into cells in vitro and in vivo is a critical technique for the study 
of genes and development of potential gene therapies. To fully utilize this potential, safer 
and more efficient vectors for delivery of genes are required. Current nucleic acid delivery 
falls into two major categories, viral and nonviral. In nonviral gene delivery, cationic lipids 
or polymers are used to both protect nucleic acids from degradation and facilitate entry into 
the target cells. The resulting complexes self-assemble via electrostatic interactions to form 
stable aggregates. Recent reports have discussed the promise of lipid-DNA (lipoplex) and 
polycation-DNA complexes (polyplexes) (77) as potential therapeutics, including recent 
efforts to incorporate bioresponsive chemistries for increased effectiveness. Successful gene 
transfer requires sufficient stability of DNA during the extracellular delivery phase, 
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transportation through cell membranes and cytoplasm, and eventual disassembly and 
nuclear delivery. A molecular architecture that achieves all the requirements will most likely 
consist of a virus like layered structure incorporating several components. Though nonviral 
gene vectors can be efficient in vitro and in vivo, their uncontrolled and often undefined 
interactions under physiological conditions still represent a major obstacle to their use in 
gene therapy. In particular, it has been shown that nonviral gene vectors or their 
constituents interact strongly with negatively charged serum proteins and other blood 
components. Such opsonization alters the physicochemical characteristics of vectors, may 
interfere with vector targeting, and is of concern if vectors are to be applied in humans. 
Consequently, one major objective in nonviral vector development is to devise vectors that 
are inert in the in vivo environment during the delivery phase. Poly (ethylene glycol) (PEG) 
has often been used to confer to these drug carriers the desired stability during the 
extracellular delivery phase. The incorporation of PEG to lipo- or polyplexes has been 
proven effective in reducing undesired effects such as immune response, unspecific 
interactions, and degradation. PEGylation can be implemented by using PEGylated compo- 
nents in the initial complex formation. Alternatively, PEG shielding can be applied to 
preformed complexes in a secondary processing step by using either electrostatic self-
assembly or chemical grafting. While PEGylation is a necessity to improve extracellular 
stability and circulation half-life, it often decreases the transfection efficiency due to reduced 
specificity and inhibited cell association and uptake. Incorporating receptor targeting or 
using bioresponsive linkers to release PEG have proven useful to overcome these 
intracellular barriers to efficient delivery (100). Previous work (100) with a copolymer-
protected gene vector (COPROG), consisting of a branched polyethylenimine (bPEI)/ DNA 
polyplex subsequently shielded with a copolymer consisting of both PEG and anionic 
peptides (P6YE5C), showed the presence of the copolymer, which provides steric 
stabilization, protection from opsonization, and allows freeze-drying of the vector with little 
loss of activity. COPROG particles have proven to be effective gene delivery vectors with 
decreased cellular toxicity without impairing gene transfer. The decreased toxicity of 
COPROG is likely a result of the removal of unbound polycation by the excess anionic 
copolymer emphasizing the potential role of binding stoichiometry in three-component 
complexes. Likely due to their stabilizing and opsonization- inhibiting properties, 
COPROGs have proven advantageous in promoting the tranfection capacity of polyplex-
loaded sponges upon subcutaneous implantation, and when colyophilized with fibrinogen, 
are a simple means to achieve an injectable fibrin gene-activated matrix (100). At the level of 
research, many synthetic DNA particles have been prepared for transfection in cell cultures 
and in animal studies. However, several authors (70).are of the opinion that, certain issues 
must be addressed in the development of DNA particles with cationic polymers. These are 
(i) potential toxicity of cationic polymers especially when administered at high 
concentrations; (ii) instability of particles on storage; (iii) instability of DNA particle size and 
particle size distribution leading to undesirable particle aggregation; (iv) poor transfection 
efficiency; (v) poor stability in blood circulation; and (vi) high cost of scaling up the process 
to achieve reproducible product quality. 
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Figure 8. Nanosize medicines  
6.4. Solid lipid nanoparticles 
Solid lipid nanoparticles (SLN) are particles made from solid lipids with mean diameters 
ranging between 50–1000nm and represent an alternative to polymeric particulate 
carriers. The main advantage offered by lipid carriers in drug delivery is the use of 
physiological lipids or lipid molecules with a history of safe use in human medicine, 
which can decrease the danger of acute and chronic toxicity (101). Sufficient data are 
available for the use of drug-loaded lipid nano and microparticles for oral delivery, the 
main mechanism of lipid particulate materials translocation across the intestine being the 
uptake via Peyer’s patches. Research reported in literature (102) shows that SLN 
constituted of stearic acid and phosphatidylcholine were evidenced in lymph and blood 
after duodenal administration to rats: the small diameters of SLN may facilitate their 
uptake by the lymphatics. Up until today, only a few methods are described in the 
literature for SLN preparation, including high pressure hot homogenization and cold 
homogenization techniques (101) microemulsion-based preparation and solvent 
emulsification/evaporation method. Particularly, the emulsification/evaporation method 
concerns the preparation of nanoparticles dispersions from O/W emulsions: the 
lipophilic material is dissolved in a water-immiscible organic solvent that is emulsified 
in an aqueous phase. Upon evaporation of the solvent, a nanoparticle dispersion is 
formed by precipitation of the lipid in the aqueous medium. Depending on the 
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composition and the concentration of the lipid in the organic phase, very low particle 
sizes can be obtained, ranging from 30–100nm, but a clear disadvantage of this method is 
the use of organic solvents, whose toxicity cannot always be neglected. Recently, an 
emulsification–diffusion technique was developed using non-toxic and physiologically 
compatible solvents and monoglycerides or waxes as components of the disperse phase 
of oil-in-water emulsions obtained at 50 oC (103). The solvent-in-water emulsion–
diffusion technique was before described in the literature mostly for the obtainment of 
polymeric micro- and nanoparticles and only a few authors proposed its application in 
the production of SLN (101). According to the moderate water solubility of the solvents 
employed, the dilution of the emulsions determined the diffusion of the organic solvent 
from the droplets to the continuous phase with the consequent instant solidification of 
lipophilic material. The emulsion compositions and process parameters used were the 
results of a formulative study aimed to develop optimized nanosphere formulations, 
whose mean sizes were below 200nm. In a separate report (104), the possibility of 
incorporating a peptide drug such as insulin in the SLN obtained with the developed 
method was considered, aiming to protect it from chemical and enzymatic degradation, 
as it is well-known that the incorporation of peptides in polymeric or non-polymeric 
particles should exert a certain protection of the drug against the proteolytic enzymes 
present in the gastrointestinal tract (101). Indeed, the use of lipids as matrix materials for 
sustained-release formulations for peptides and proteins has been reported only by few 
authors (101), owing to the hydrophobic nature of the lipid matrix that can be more 
appropriate to incorporate lipophilic drugs rather than hydrophilic proteins. An 
adequately high solubility of the drug in the lipid melt is therefore the pre-requisite to 
obtain a sufficient SLN loading capacity. Considering that the solubility of insulin in 
most commonly employed solvents and lipids is quite low, a specific solvent medium of 
the peptide was required. Isobutyric acid, a partially water-miscible solvent with low 
toxicity, revealed a totally unexpected high insulin-solubilization capacity at 50 oC, 
further increasing when the solvent was water-saturated (104). Solid lipid insulin-loaded 
microparticles were therefore produced using isobutyric acid as a solvent. Preliminary 
analysis of microparticles content after processing showed an insulin-high encapsulation 
efficiency; moreover, insulin in SLN did not undergo any chemical modification and its 
in vitro release from the microparticles was very low, with an initial burst effect of 20% 
of the dose. 
Of recent, SLN has become a popular drug delivery system for ophthalmic application. It 
is gaining prominence as promising approach to improve the poor ocular bioavailability 
of biomolecules. In particular, solid lipid nanoparticles (SLN) and nanostructured lipid 
carriers (NLC), regarded as the first and second generation of lipid nanoparticles are 
currently being applied.(105, 106) NLC was developed due by combining the advantages 
of SLN and avoidance of their limitations such as low drug loading capacity, poor long-
term stability and early drug expulsion caused by lipid polymorphism.(107, 108) NLC 
consist of a mixture of spacially different solid and liquid lipids molecules, resulting in a 
structure with more imperfections in crystal lattice to accommodate drugs.(109, 110) As 
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drug delivery devices, NLC show great promise for the eye, due to their better 
biocompatibility, modified drug release kinetics, reduction of drug leakage during 
storage, avoidance of organic solvents during production process and feasibility of large 
scale production.(111, 112) 
To prepare particles using the homogenization method, the drug is dissolved or solubilized 
in the lipid that has been melted and heated to a temperature approximately 5–10 oC above 
its melting point. For the hot homogenization technique, the drug dissolved in the lipid melt 
is dispersed under stirring in a hot aqueous surfactant solution of identical temperature. The 
obtained pre-emulsion is homogenized to produce nanoemulsions that are subsequently 
cooled to room temperature. Solid lipid nanoparticles are obtained upon lipid 
recrystallization at room temperature. Some of the process variables that will affect the 
particle size of nanoparticles as well as drug loading are (i) the type of homogenization 
technique; (ii) speed of homogenization; and (iii) rate of cooling in hot homogenization. 
Cold homogenization is applied for highly temperature-sensitive drugs and hydrophilic 
drugs. For the cold homogenization technique the drug containing lipid melt is cooled and 
ground to obtain lipid particles. The lipid particles are dispersed in a cold surfactant 
solution that is homogenized at or below room temperature. The process avoids or 
minimizes the melting of lipids and therefore minimizing the loss of hydrophilic drugs to 
the water surface. Solid lipid nanoparticles can also be prepared by using microemulsions as 
precursors.  
7. Characterization of nanoparticles 
Measurement of nanoparticles can be carried out by photon correlation spectroscopy 
(PCS) or dynamic light scattering (DLS). Photon correlation spectroscopy determines  
the hydrodynamic diameter of the nanoparticles by Brownian motion. In addition to the 
size, other important properties of nanoparticles include (i) density, molecular weight  
and crystallinity which can affect drug release and degradation; (ii) surface charge and 
hydrophobicity which may significantly influence nanoparticle behavior after 
administration. Zeta potential is also one of the properties of nanoparticles, and  
this is usually employed to measure the cell-surface charge density. The surface and  
bulk morphology are also important in determining the drug release kinetics of 
nanoparticles. Nanoparticles are usually visualized by scanning electron microscope 
(SEM) and atomic force microscopy (AFM). Thermal profile of nanoparticles can be 
studied using the differential scanning calorimetry (DSC), thermogravimetric analysis 
(TGA), while crystallinity can be monitored by x-ray crystallography. Other  
parameters which should normally be evaluated include; drug encapsulation efficiency; 
physical properties such as size, shape, stability of size, drug loading as well as drug 
release.  
The common techniques for characterization as summarized by B. K. Nanjwade is shown in 
Tabs 5 – 8 below: 
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Morphology
Properties Common Techniques
Size (primary particle) TEM, SEM, AFM, XRD
Size (primary/aggregate/agglomerate) TEM, SEM, AFM, DLS, FFF, AUC, 
CHDF, XDC, HPLC, DMA(1)
Size distribution EM, SEM, AFM, DLS, AUC, FFF, 
HPLC, SMA
Molecular weight SLS, AUC, GPC
Structure/Shape TEM, SEM, AFM, NMR 
Stability (3D structure) DLS, AUC, FFF, SEM, TEM
Source: B. K. Nanjwade api.ning.com/.../DevelopmentofNanotechnologyBasedDrugsanditsGu 
Table 5.  
Surface
P roperties Common Techniques
Surface area BET 
Surface charge SPM, GE, Titration methods
Zeta potential LDE, ESA, PALS
Surface coating composition SPM, XPS, MS, RS, FTIR, NMR
Surface coating coverage AFM, AUC, TGA
Surface reactivity Varies with nanomaterial
Surface-core interaction SPM, RS, ITC, AUC, GE 
Topology SEM, SPM, MS
Source: B. K. Nanjwade api.ning.com/.../DevelopmentofNanotechnologyBasedDrugsanditsGu 
Table 6.  
Chemical
Properties Common Techniques
Chemical composition (core, surface) XPS, MS, AAS, ICP-MS, RS, FTIR, 
NMR
Purity ICP-MS, AAS, AUC, HPLC, DSC
Stability (chemical) MS, HPLC, RS, FTIR
Solubility (chemical) Varies with nanomaterial
Structure (chemical) NMR, XRD
Crystallinity XRD, DSC 
Catalytic activity Varies with nanomaterial
Source: B. K. Nanjwade api.ning.com/.../DevelopmentofNanotechnologyBasedDrugsanditsGu 
Table 7.  
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Other 
Properties Common Techniques
Drug loading MS, HPLC, UV-Vis, varies with 
nanomaterial
Drug potency/functionality Varies with nanomaterial
In vitro release (detection) UV-Vis, MS, HPLC, varies with 
nanomaterial
Deformability AFM, DMA(2)
Source: B. K. Nanjwade api.ning.com/.../DevelopmentofNanotechnologyBasedDrugsanditsGu 
Table 8.  
8. Nanoparticle application in non-parenteral applications 
8.1. Oral administration 
For many reasons, oral drug delivery continues to be the preferred route of drug 
administration. It is the oldest and the commonest mode of drug administration as it is safer, 
more convenient, does not need assistance, non-invasive, often painless, the medicament 
need not be sterile and so is cheaper (113). However, the oral route is not suitable for drugs 
that are poorly permeable or easily degradable in the gastrointestinal tracts (GIT). For 
instance, delivery of proteins and peptides via the oral route will be greatly impacted by 
barriers such as (i) epithelial cell lining; (ii) the mucus layer; (iii) proteolytic enzymes in the 
gut lumen (such as pepsin, trypsin and chymotrypsin); and (iv) proteolytic enzymes 
(endopeptidases), at the brush border membrane. Drug loaded in nanoparticles will be 
protected from the enzymatic degradation along the GIT providing the potential benefit of 
enhanced absorption. It has been reported (70) that, particulate absorption takes place 
mainly at the intestinal lymphatic tissues (the Peyer’s patches). The epithelial cell layer 
overlying the Peyer’s patches contains Mcells. The differences between absorptive 
enterocytes and M cells are expressed in that M cells have (a) underdeveloped microvillous 
and glycocalyx structures, (b) apical microfolds, (c) increased intracellular vacuolization and 
(d) absence of mucus. The follicle-associated epithelia (FAE) are made up of the M cells and 
absorptive enterocytes (70). It has been reported that, the FAE and Mcells are predominantly 
responsible for particle uptake along the GIT. In this regard, nanotechnology is reportedly 
gaining attention in the development of proteins, peptides and DNA delivery systems (70).  
8.2. Pulmonary administration 
Micronization of drugs plays an important role in improving the drug dosage form and 
therapeutic efficiency today. If a drug is micronized into microspheres with suitable 
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particle size, it can be addressed directly to the lung by the mechanical interception of 
capillary bed in the lungs. If a drug is prepared as microspheres in the size range of 7–25 
µm, the microspheres can be concentrated in lung through i.v. administration (114). This 
technique can improve pulmonary drug concentration to maximize its effectiveness 
against some pulmonary infections such as mycoplasmal pneumonia and minimize the 
adverse side effects. The final nanoparticulate formulation may be administered either as 
a nebulizer (metered dose inhalers) or dry powder inhalers. Local delivery of drugs to the 
lung is desirable for many clinical conditions such as asthma; chronic pulmonary 
infections, lung cancer and cystic fibrosis. For both local and/or systemic delivery,  
the effectiveness of drug delivery by inhalation may be greatly imparted by mucociliary 
clearance (70). Studies have shown that nanoparticles may facilitate transport of drugs  
to the epithelium while avoiding undesirable mucociliary clearance. Other benefits of 
nanoparticle-based formulations are in the suitability for (i) sustained drug effect due  
to possible prolonged residence of drug at the site of action or absorption; (ii) controlled 
or targeted drug delivery. The small size of nanoparticles makes them highly suitable  
for pulmonary delivery because they can easily be air borne and delivered to the alveolus. 
It is important that the components of the nanoparticle formulation are biodegradable  
to avoid accumulation in the lungs and that they do not cause irritation of the air ways 
and lung tissue. The control of the particle size of the formulation during manufacture 
and the entire shelf life of the drug product is also very important for an acceptable 
product (70). 
8.3. Topical administration 
As noted by Majuru and Oyewumi (70) the feasibility of applying nanoparticles in 
topical/cosmetic preparations has been a subject of several commentaries. In any case, this 
dosage form utilizes the advantages of nanoparticles such as (a) protection of labile 
compounds; (b) controlled release of incorporated drugs; (c) ability of solid lipid 
nanoparticles to act as occlusive to increase the water content of the skin; and (d) ability of 
nanoparticles to serve as physical barriers on the skin for blocking UV light and, as such, for 
use in sunscreen formulations.  
9. Conclusions 
Drug Delivery scientists are searching for the ideal nanovehicle for the ideal nanodrug 
delivery system; one that would dramatically reduce drug dosage, such that, there is 
improvement in the absorption of the drug, so that the patient can take a smaller dose, 
and yet have the same benefit, Deliver the drug to the right place in the living system, 
Increase the local concentration of the drug at the desired site and limit or eliminate side 
effects. As it stands today, the scope of this emerging field seems to be limitless. However, 
considerable technological and financial obstacles still need to be properly addressed by 
both the private sector and governments before nanotechnology’s full promise can be 
realized. Ranking highest among the challenges is the need to develop and perfect reliable 
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techniques to produce nanoscale particles that does not just have the desirable particle 
sizes, but also minimal structural defects and acceptable purity levels. This is because 
these attributes can drastically alter the anticipated behavior of the nanoscale particles. 
Moving today’s promising nanotechnology-related developments from laboratory- and 
pilot-scale demonstrations to full-scale commercialization is still a big challenge and 
nanotechnology scientists must gear up to these challenges. Nanotechnology, deals with 
the design, characterization, production and application of structures, devices and 
systems by controlling shape and size at the nanometer scale. Two principal factors cause 
the properties of nanomaterials to differ significantly from other materials: increased 
relative surface area, and quantum effects. These factors can change or enhance properties 
such as reactivity, strength, electrical characteristics as well as most of the biomedical 
properties. Nanotechnology in biomedical sciences is expected to create innovations and 
play a vital role, not only in drug delivery and gene therapy, but also in molecular 
imaging, biomarkers and biosensors. Today the application of nanotechnology in drug 
delivery is widely expected to change the landscape of pharmaceutical and biotechnology 
industries for the foreseeable future. Target-specific drug therapy and methods for early 
diagnosis of pathologies are the priority research areas where nanotechnology would play 
a prominent role. Using nanotechnology, it may be possible to achieve (1) improved 
delivery of poorly water-soluble drugs; (2) targeted delivery of drugs in a cell- or tissue-
specific manner; (3) transcytosis of drugs across tight epithelial and endothelial barriers; 
(4) delivery of large macromolecule drugs to intracellular sites of action; (5) co-delivery of 
two or more drugs or therapeutic modality for combination therapy; (6) visualization of 
sites of drug delivery by combining therapeutic agents with imaging modalities; and (7) 
real-time read on the in vivo efficacy of a therapeutic agent. For example, with more than 
10 million new cases every year, cancer has become one of the most devastating diseases 
worldwide, yet, the most common cancer treatments are limited to chemotherapy, 
radiation, and surgery. Although conventional treatment options such as chemotherapy 
and radiation have experienced many advances over the past decades, cancer therapy is 
still far from optimal. Frequent challenges encountered by the current cancer therapies 
include nonspecific systemic distribution of antitumor agents, inadequate drug 
concentrations reaching the tumor, and the limited ability to monitor therapeutic 
responses. Poor drug delivery to the target site leads to significant complications, such as 
multidrug resistance, here nanodrug delivery holds great promise. A large number of 
nanocarriers have been designed for delivery of peptides via liposomes, noisome, 
polymeric nanoparticles, solid lipid nanoparticles etc. Polymeric based nanoparticles have 
taken much attention for safe and effective delivery of proteins. Nanoparticles prepared, 
particularly in the size range from 10 nm to 100 nm, are considered optimal for cancer 
therapeutics. Thus multifunctional nanoparticles combining different functionalities like 
targeting, imaging and therapy into one system can be used for effective cancer treatment. 
Multifunctional nanoparticles hold great promise for the future of cancer treatment 
because they can detect the early onset of cancer in each individual patient and deliver 
suitable therapeutic agents to enhance therapeutic efficacy. The combination of tumor-
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targeted imaging and therapy in an all-in-one system provides a useful multimodal 
approach in the battle against debilitating health conditions like cancer. Despite the 
promise of many of the early nanotechnology-related breakthroughs, the ability to 
develop cost-effective, commercially and technically viable applications for these 
laboratory wonders will ultimately be predicated on the research community’s ability to 
bridge the gap—some might say chasm—between the science involved and engineering 
required, particularly during scale up.  
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